Publications

Drug Information Group faculty regularly publish articles on a variety of topics in peer-reviewed journals and other educational formats.

Recent Publications (2008 - Present)

  • Nathan J, Grossman S, Ness G, Gabay M, Ipema H, Tierno H.  Update on the status of drug information centers in the United States.  Am J Health-Syst Pharm. 2020;77(1):33-38.
  • Sarna KV, Griffin T, Tarlov E, Gerber BS, Gabay MP, Suda KJ.  Trends in gender composition on editorial boards in leading medicine nursing, and pharmacy journals.  J Am Pharm Assoc. 2020. pii: S1544-3191(19)30609-0. doi: 10.1016/j.japh.2019.12.018. [Epub ahead of print].
  • Spencer SH, Menard SM, Labedz MZ, Krueger CD, Sarna KV. Enteral tube administration of oral chemotherapy drugs. J Oncol Pharm Pract. 2020 Jan 19:1078155219893449. doi: 10.1177/1078155219893449. [Epub ahead of print]
  • Ipema H, Zacher J, Galka E, et al. Drugs to be used with a filter for preparation and/or administration. Hosp Pharm. 2019. https://journals.sagepub.com/doi/epub/10.1177/0018578719867660. doi: 10.1177/0018578719867660.
  • Miles K, Zacher J. A physician primer: drugs with orphan designations for the treatment of pain conditions. Practical Pain Management. 2019. Available at: https://www.practicalpainmanagement.com/resources/practice-management/physician-primer-drugs-orphan-designations-treatment-pain-conditions?fbclid=IwAR00bFHTLtzYJvpnDRYaDA4H1TZC0Gota6X1Zf1pNmui04XB-POuOmBIaVg
  • Endriukaitis LA, Hayes GL, Mills J. Economic evaluation of changes in reimbursement for medications purchased through the 340b drug pricing program. Hosp Pharm. November 2019: doi:10.1177/0018578719888907.
  • Lee M, Saseen J, Beckman E, Coon S, Gabay M, Japs K, Mangan B, McBane S, See S.  ACCP Commentary. Expanding the pharmacist’s scope of practice at the state level: support for board certification within the credentialing process. J Am Coll Clin Pharm. 2019 [In Press].
  • Gabay M.  The Orphan Drug Act: an appropriate approval pathway for treatments of rare diseases?  Hosp Pharm. 2019;54(5):283-284.
  • Gabay M, Hertig JB, Degnan D, Burger M, Yaniv A, McLaughlin M, Moody ML.  Third Consensus Development Conference on the Safety of Intravenous Drug Delivery Systems – 2018.  Am J Health-Syst Pharm. 2019. Dec 7. pii: zxz277. doi: 10.1093/ajhp/zxz277. [Epub ahead of print]
  • Gerberich A, Spencer S, Ipema H. National Guideline Clearinghouse is no more – keep calm and search on. Ann Pharmacother. 2019;53(4):434-436.
  • Spencer S. Immunotherapy toxicities: early recognition and management. Pharmacy Practice News. Published September 16, 2019. https://www.pharmacypracticenews.com/Review-Articles/Article/09-19/Immunotherapy-Toxicities-Early-Recognition-and-Management/55937
  • Rodriguez R, Koppen L, Patel YA, Ellinger, LK. Characteristics of shortage-related drug information requests and recommendations from a nationally-serving drug information center. Am J Health Syst Pharm. 2019;76(23):1900-1902. doi: 10.1093/ajhp/zxz230.
  • Afanasjeva J. Moderate to severe atopic dermatitis: options for disease management. Pharmacy Practice News. October 2019. Available at: https://www.pharmacypracticenews.com/Review-Articles/Article/10-19/Moderate-to-Severe-Atopic-Dermatitis/56139
  • Caudle KE, Gammal RS, Karnes JH, Afanasjeva J, Anderson KC, Barreto EF, et al. PRN opinion paper: application of precision medicine across pharmacy specialty areas. J Am Coll Clin Pharm. 2019;2:288-302.
  • Afanasjeva J, Gruenberg K. Pharmacists as environmental stewards: strategies for minimizing and managing drug waste. Sustain Chem Pharm. 2019;13: 100164. doi: 10.1016/j.scp.2019.100164
  • Sarna KV, Gross AE. Vancomycin versus metronidazole for non-severe Clostridioides difficile infection: are the data adequate to change practice? Ann Pharmacother. 2019.53(8):845-852.
  • Loeser K, Rodriguez R. Abuse-deterrent opioids: regulatory and evidence-based considerations for front-line clinicians. Am J Health Syst Pharm. 2019;76(2):114-118. doi: 10.1093/ajhp/zxy013.
  • Rodriguez R, Fernandez EM. The role of angiotensin II in treatment of refractory distributive shock. Am J Health Syst Pharm. 2019;76(2):101-107. doi: 10.1093/ajhp/zxy014.
  • Rodriguez R. The science of biosimilars and the future of interchangeability. Pharm Pract News. 2019:41-45.
  • Rodriguez R, Cucci M, Kane S, Fernandez E, Benken S. Novel vasopressors in the treatment of vasodilatory shock: a systematic review of angiotensin II, selepressin, and terlipressin. J Intensiv Care Med. 2018. doi: 10.1177/0885066618818460.
  • Rodriguez R. The safety of intravenous drug delivery systems: update on current issues since the 2009 Consensus Development Conference. Hosp Pharm. 2018;53(6):408-414. doi: 10.1177/0018578718798638.
  • Afanasjeva J, Majkowski C, Campbell C. New oral oncolytics of 2017: key points for a counseling pharmacist. KeePosted. June 2018;44(5). Available at: https://ichpnet.org/keeposted/article/44/05/educational_affairs
  • Campbell C, Afanasjeva J, Majkowski C. New oncology drugs of 2017: novel intravenous approvals. KeePosted.  March/April 2018; 44(3). Available at: https://ichpnet.org/keeposted/article/44/03/educational_affairs
  • Rasmussen JT, Ipema HJ. Formulary considerations for insulins approved through the 505(b)(2) ‘follow-on’ pathway. Ann Pharmacother. 2019;53(2):204-210.
  • Spencer S, Majkowski C, Suda KJ. Publication rates and predictors of publication for abstracts presented at American Association of Colleges of Pharmacy (AACP) annual meetings. Am J Pharm Educ. 2018;82(8):6409.
  • Koppen L, Suda K, Rowan S, McGregor J, Evans C. Dentists’ prescribing of antibiotics and opioids to Medicare Part D beneficiaries: medications of high impact to public health. J Am Dent Assoc. 2018;149(8):721-730.
  • Gabay M. RxLegal: a rapid review of right-to-try. Hosp Pharm.2018;53(4):234-235.
  • Gabay M. The prescription drug user fee act: cause for concern? Hosp Pharm. 2018;53(2):88-89.
  • Spencer S, Ipema H, Hartke PKrueger C, Rodriguez R, Gross AE, Gabay M. Intravenous push administration for antibiotics: An alternative method. Hosp Pharm. 2018;53(3):157-169.
  • Gabay M. Biosimilar substitution laws. Hosp Pharm. 2017. 52(8):544-545.
  • Gabay M. Direct and indirect remuneration fees: the controversy continues. Hosp Pharm. 2017;52(11):740-741.
  • Koppen L, Whitaker A, Rosene A, Beckett R. Effect of berberine alone and in combination for the treatment of hyperlipidemia: a systematic review. J Evid Based Complementary Altern Med. 2017;22(4):956-968.
  • Gabay M. The evolution of drug information centers and specialists. Hosp Pharm. 2017;52(7):452-453.
  • Gabay M. 21st Century Cures Act. Hosp Pharm. 2017;52(4):264-265.
  • Gabay M, Smith J, Chavez M, et al. White paper on natural products. Pharmacotherapy. 2017;37(1):e1-e15.
  • Afanasjeva J. Administration of injectable vitamin K orally. Hosp Pharm. 2017;52(9):645-649.
  • Rodriguez R, Kelly B, Moody M. Evaluating the training, responsibilities, and practices of P&T committee members and nonmember contributors. Journal of Managed Care and Specialty Pharmacy. 2017;23(8):868-874.
  • Rodriguez R, Soni R. Psoriatic arthritis: established, newer, and emerging therapies. Practical Pain Management. 2017;17(6). Available at: https://www.practicalpainmanagement.com/pain/myofascial/inflammatory-arthritis/psoriatic-arthritis-established-newer-emerging-therapies.
  • Shah J, Rodriguez R. Are abuse-deterrent opioid products a double-edged sword? Practical Pain Management. 2017;17(4):45-53.
  • Koppen L, Afanasjeva J. A brief history of the FDA’s role in the ongoing effort to ensure safe opioid use. Practical Pain Management. 2017;17(1). Available at: https://www.practicalpainmanagement.com/treatments/pharmacological/opioids/brief-history-fda-role-ongoing-effort-ensure-safe-opioid-use.
  • Afanasjeva J, Hui RL, Spence MM, et al. Identifying subsequent therapies in patients with advanced non-small-cell lung cancer and factors associated with overall survival. Pharmacotherapy. 2016;36(10):1065-1074.
  • Rodriguez R. Comparison of indexing times among articles from medical, nursing, and pharmacy journals. Am J Health Syst Pharm. 2016;73(8):569-575.
  • Gabay M.  Drug prices: is there a need for transparency?  Hosp Pharm. 2016;51(2):132-133.
  • Spencer S, Suda KJ, Smith MJ, Huo Z, Bailey L, Stroupe KT. Erectile dysfunction medication use in veterans eligible for Medicare Part D. J Manag Care Spec Pharm. 2016;22(7):818-824.
  • Bursua A, Hartke PL, Larson CM. Benchmarking and medication error rates. Am J Health Syst Pharm. 2016;73(11):744.
  • Gabay M. Increasing access to naloxone and legal issues. Hosp Pharm. 2016;51(8):633-364.
  • Hartke P, Afanasjeva J. Sports-related pain: topical treatments. Practical Pain Management. 2016;16(4). Available at: http://www.practicalpainmanagement.com/treatments/pharmacological/non-opioids/sports-related-pain-topical-treatments.
  • Hartke PL, Vermeulen LC, Hoffman JM, et al. Accuracy of prescription drug expenditure forecasts published in the AJHP. Am J Health Syst Pharm. 2015;72(19):1642-1648.
  • Koppen L, Phillips J, Papageorgiou R. Analysis of reference sources used in drug-related Wikipedia articles. J Med Libr Assoc. 2015;103(3):140-144.
  • Afanasjeva J. Have you considered a drug information residency? California Journal of Health-System Pharmacy. 2015;27(5):153-156.
  • Gabay M.  FAST Generics Act of 2015.  Hosp Pharm. 2016;51(1):42-43.
  • Zych KIpema H. Psoriasis and psoriatic arthritis: update in management. Specialty Pharmacy Continuum. January/February 2016. Available at: http://www.specialtypharmacycontinuum.com/download/psoriasis_spc0116_WM.pdf.
  • Ghaibi S, Ipema HJGabay MG. ASHP guideline on the pharmacist’s role in providing drug information. Am J Health Syst Pharm. 2015;72(7):573-577.
  • Gabay MThe Clinical Practice of Drug Information. 1st ed. Sudbury (MA): Jones & Bartlett Learning: 2015.
  • Gabay M, McKeever AL. Introduction to drug information practice. In: Gabay M, ed. The Clinical Practice of Drug Information. 1st ed. Sudbury (MA): Jones & Bartlett Learning; 2015:1-10.
  • Rodriguez RW. Analysis and interpretation of noninferiority trials. In: Gabay M, ed. The Clinical Practice of Drug Information. 1st ed. Sudbury (MA): Jones & Bartlett Learning: 2015;195-212.
  • Gabay M, Grando Holman Y. Academic detailing and industry relationships. In: Gabay M, ed. The Clinical Practice of Drug Information. 1st ed. Sudbury (MA): Jones & Bartlett Learning: 2015;409-424.
  • Ipema HJ, Tanzi MG. Medical writing and peer review. In: Gabay M, ed. The Clinical Practice of Drug Information. 1st ed. Sudbury (MA): Jones & Bartlett Learning; 2015:
  • Gabay MP, Wirth SM, Stachnik JM, Overley CL, Long KE, Bressler LR, Villano JL.  Oral targeted therapies and central nervous system (CNS) metastases.  CNS Drugs. 2015;29(11):935-952.
  • Gabay M.  Regulation of internet pharmacies: a continual challenge.  Hosp Pharm. 2015;50(8):681-682.
  • Gabay M. Providing feedback to colleagues: a continual challenge. Hosp Pharm. 2015;50(4):259-260.
  • Gabay M. Prescription drug monitoring programs. Hosp Pharm. 2015;50(4):277-278.
  • Reddy A, Gabay M. Brintellix (vortioxetine) review. Illinois Pharmacist. 2014;76(3):26-29.
  • Gabay M. The Drug Quality and Security Act. Hosp Pharm. 2014;49(7):615-616.
  • Gabay M. USP : Handling hazardous drugs. Hosp Pharm. 2014;49(9):811-812.
  • Krueger C. New treatments for rheumatoid arthritis. Specialty Pharmacy Continuum. 2014;4(3):8-10.
  • Rodriguez RW. Off-label uses of alvimopan and methylnaltrexone. Am J Health Syst Pharm. 2014;71(17):1450-1455.
  • Letarte N, Gabay MP, Bressler LR, Long KE, Stachnik JM, Villano JL. Analyzing temozolomide medication errors: potentially fatal. J Neurooncol. 2014;120(1):111-115.
  • Fisseha N, Rodriguez RIpema H. Olysio (simeprevir) Review. Illinois Pharmacist. 2014;26(2):26-27.
  • UIC Drug Information Group. Light-sensitive injectable prescription drugs. Hosp Pharm. 2014;49(2):136-163.
  • Gabay M. Federal controlled substances act:  dispensing requirements, electronic prescriptions, and fraudulent prescriptions. Hosp Pharm. 2014;49(3):244-246.
  • Gabay M. A step forward: review of the new California Provider Status law. Hosp Pharm. 2014;49(5):435-436.
  • Rodriguez RW. Delay in indexing of articles published in major pharmacy practice journals. Am J Health Syst Pharm. 2014;71(4):321-324.
  • Rodriguez RW. How safe is epidural steroid injection? Examining drug-related factors. Practical Pain Management. 2014;14(2):31-35. Available at: http://www.practicalpainmanagement.com/treatments/interventional/injections/how-safe-epidural-steroid-injection-examining-drug-related.
  • Rodriguez R, Ellinger LK. Rheumatoid arthritis treatment guidelines updated (update). In: Talbert RL, DiPiro JT, Matzke GR, Posey LM, Wells BG, Yee GC, eds. Pharmacotherapy: A Pathophysiologic Approach. 8th ed. New York: McGraw-Hill; 2013.
  • Rodriguez RW, Staley B, Hatton RC. Evaluating incorporation of drug restrictions into computerized drug order entries after transition to an electronic health record. Hosp Pharm. 2013;48(7):568-573.
  • Stachnik JM, Krueger CD. Infertility in women. In: Murphy JE, Lee MW, eds. Pharmacotherapy Self-Assessment Program, 2013 Book 2. Special Populations. Lenexa, KS: American College of Clinical Pharmacy, 2013:61-76.
  • Gabay M, Boucher BA.  An essential primer for understanding the role of topical hemostats, surgical sealants, and adhesives for maintaining hemostasis.  Pharmacotherapy. 2013;33(9):935-955.
  • Gabay M.  Federal controlled substances act: ordering and recordkeeping.  Hosp Pharm. 2013;48(11):919-921.
  • Gabay M.  Federal controlled substances act: controlled substances prescriptions.  Hosp Pharm. 2013;48(8):644-645.
  • Gabay M.  The federal controlled substances act:  schedules and pharmacy registration.  Hosp Pharm. 2013;48(6):473-474.
  • Gabay M.  Expanding the definition of nonprescription drugs: potential impact on pharmacists.  Hosp Pharm. 2013;48(3):198-199.
  • Krueger C. Ask The Expert: I have recently read a lot on twitter that NSAIDs cause more deaths than opioids. Can you clarify if this is true? Practical Pain Management. 2013;13(10). Available at: http://www.practicalpainmanagement.com/treatments/pharmacological/opioids/ask-expert-do-nsaids-cause-more-deaths-opioids.
  • Ipema HJ. Use of oral vitamin K for prevention of late vitamin K deficiency bleeding in neonates when injectable vitamin K is not available. Ann Pharmacother. 2012;46(6):879-883.
  • Ipema HJ, Tanzi MG. Use of topical tranexamic acid and aminocaproic acid to prevent bleeding after major surgical procedures. Ann Pharmacother. 2012:46(1):97-107.
  • UIC Drug Information Group. Drugs that require filtration for preparation or administration. Hosp Pharm. 2012;47(5):351-359.
  • Phillips JA, Gabay MP, Ficzere C, Ward KE. Curriculum and instructional methods for drug information, literature evaluation, and biostatistics: survey of US pharmacy schools. Ann Pharmacother. 2012;46(6):793-801.
  • Gabay MP, Thakkar JP, Stachnik JM, Woelich SK, Villano JL. Intra-CSF administration of chemotherapy medications. Cancer Chemother Pharmacol. 2012;70(1):1-15.
  • Gabay M. Tech-check-tech: an overview. Hosp Pharm. 2012;47(6):444-445.
  • Gabay M. Drug importation: where do we stand? Hosp Pharm. 2012;47(2):110-111.
  • Stachnik J, Gabay M. Biologics in pediatrics. In: Field M, Boat T, eds. Supporting the Review of Best Pharmaceuticals for Children Act and Pediatric Research. Institute of Medicine of the National Academies. Released February 29, 2012. Available at: http://www.iom.edu/Reports/2012/Safe-and-Effective-Medicines-for-Children.aspx.
  • Lodolce AE, Krueger CD. Managing anemia in patients with chronic kidney disease. Pharmacy Practice News. 2012;39. Available at: http://www.pharmacypracticenews.com/download/Anemia_ppn0612_WM.pdf.
  • Krueger C. Methadone for pain management. Practical Pain Management. 2012;12(2). Available at: http://www.practicalpainmanagement.com/treatments/pharmacological/opioids/methadone-pain-management.
  • Ghaibi S, Ipema H. Proper disposal of fentanyl patches: what patients need to know. Practical Pain Management. 2012;12(10). Available at: http://www.practicalpainmanagement.com/treatments/pharmacological/opioids/proper-disposal-fentanyl-patches-what-patients-need-know.
  • Segreti J, Garcia-Houchins S, Gorski L, Moureau N, Shomo J, Zack J, Stachnik J, Tanzi M, Moody ML. Consensus conference on prevention of central line-associated bloodstream infections: 2009. J Infus Nurs. 2011;34(2):126-133.
  • Hong IS, Ipema HJ, Gabay MP, Lodolce AE. Medication repurposing: new uses for old drugs. J Pharm Technol. 2011;27(3):132-140.
  • Gabay M. Pharmacists and prescriptive authority. Hosp Pharm. 2011;46(11):852-853.
  • Gabay M. FDA citizen petition process. Hosp Pharm. 2011;46(8):572-573.
  • Gabay M. Pharmacist conscience clauses: continuing debate. Hosp Pharm. 2011;46(5):330-331.
  • Gabay M. Emily’s law: requiring minimum education and training standards for pharmacy technicians. Hosp Pharm. 2011;46(2):103-104.
  • Ipema HJ, Lodolce AE, Mancuso CE. Survey of drug information activities of ASHP-accredited pharmacy practice residency programs. Am J Health Syst Pharm. 2011;68(13):1194-1195.
  • Burda AT, Ipema HJ, Wahl MS. Self-treatment of acetaminophen overdose with dietary-supplement acetylcysteine. Am J Health Syst Pharm. 2011;68(9):786-787.
  • Krueger C.  Medications for chronic pain – other agents. Practical Pain Management. 2011;11(5):90-99. Available at: http://www.practicalpainmanagement.com/treatments/pharmacological/medications-chronic-pain-other-agents.
  • Krueger C. Management of warfarin therapy. Pharmacy Practice News. 2011;38:43-50 (updated 2012). http://www.pharmacypracticenews.com/download/warfarin_therapy_ppn1212_WM.pdf.
  • Gabay M. Academic detailing and the IDEA act. Hosp Pharm. 2010;45(11):839-840.
  • Hong I, Gabay M, Lodolce A. Safety concerns involving transdermal patches and magnetic resonance imaging (MRI). Hosp Pharm. 2010;45(10):771-778.
  • Mancuso CE, Gabay MP, Steinke LM, VanOsdol SJ. Peramivir: an intravenous neuraminidase inhibitor for the treatment of 2009 H1N1. Ann Pharmacother. 2010;44(7-8):1240-1249.
  • Ellinger LK, Ipema HJ, Stachnik JM. Efficacy of metformin and topiramate in prevention and treatment of antipsychotic-induced weight gain. Ann Pharmacother. 2010;44(4):668-679.
  • Krueger C.  Management of epidermal growth factor inhibitor-induced dermatologic toxicity.  Pharmacy Practice News. 2010;37:16-20. Available at: http://www.pharmacypracticenews.com/download/epidermalgrowth_ppn0410_WM.pdf.
  • Ipema HJ, Jung MY, Lodolce AE. Romiplostim management of immune thrombocytopenic purpura. Ann Pharmacother. 2009;43(5):914-919.
  • Sanborn M, Gabay M, Moody ML. The safety of intravenous drug delivery systems: update on current issues since the 1999 consensus development conference. Hosp Pharm. 2009;44(2):159-164.
  • Sanborn MD, Moody ML, Harder KA, Pepper GA, Scanlon M, Vaida AJ, et al. Second consensus development conference on the safety of intravenous drug delivery systems—2008. Am J Health Syst Pharm. 2009;66(2):185-192.
  • Gabay M, von Martius K. Comparative evaluation of collapsible versus semi-rigid intravenous containers. Technol Health Care. 2008;16(6):429-435.